文献速递肝病消化道肿瘤与早癌

慢性乙型肝炎患者接受长期恩替卡韦或替诺福韦治疗的八年生存率与一般人群相似

Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population.
PubMed 文献 · J Hepatol · 2018-02-08

这项正在进行的10中心队列研究纳入1951例接受恩替卡韦或替诺福韦治疗至少12个月(中位6年)的成人高加索慢性乙型肝炎患者,评估长期抗病毒治疗后的生存概率及影响因素。结果显示八年总生存率为94.1%,肝病相关生存率为97.4%,无移植肝病相关生存率为95.8%;总体死亡率与一般人群无显著差异(SMR 0.82),肝细胞癌是影响总体死亡率和肝病相关死亡率的唯一独立因素。

要点

  • 八年总生存率94.1%,肝病相关生存率97.4%,无移植肝病相关生存率95.8%。
  • 总体死亡率与一般人群无显著差异(SMR 0.82)。
  • 肝细胞癌是影响总体死亡率和肝病相关死亡率的唯一独立因素。

核心结论

  • 接受长期恩替卡韦或替诺福韦治疗的高加索慢性乙型肝炎且代偿性肝病患者,八年总体生存率和肝病相关生存率极好,与一般人群相似。
  • 肝细胞癌是影响总体死亡率的主要因素,也是影响肝病相关死亡率的唯一因素。

研究设计与样本

  • 正在进行的10中心队列研究,纳入1951例成人高加索慢性乙型肝炎患者,基线时伴或不伴代偿性肝硬化且无肝细胞癌,接受恩替卡韦或替诺福韦治疗至少12个月(中位6年)。
  • 采用Kaplan-Meier法估计累积生存率,通过比较死亡 rates 与人类死亡率数据库计算标准化死亡比(SMR)。

主要发现

  • 1年、5年和8年累积概率分别为:总生存率99.7%、95.9%、94.1%;肝病相关生存率99.9%、98.3%、97.4%;无移植肝病相关生存率99.9%、97.8%、95.8%。
  • 总体死亡率独立相关因素为年龄较大和发生肝细胞癌;肝病相关死亡率仅与发生肝细胞癌相关;无移植肝病相关死亡率独立相关因素为发生肝细胞癌和基线血小板水平较低。
  • 基线肝硬化与任何类型的死亡率均无独立关联。
  • 与一般人群相比,所有慢性乙型肝炎患者死亡率无显著差异(SMR 0.82);无肝细胞癌患者死亡率较低(SMR 0.58),发生肝细胞癌患者死亡率较高(SMR 3.09)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The effects of long-term antiviral therapy on survival have not been adequately assessed in chronic hepatitis B (CHB). In this 10-centre, ongoing cohort study, we evaluated the probability of survival and factors affecting survival in Caucasian CHB patients who received long-term entecavir/tenofovir therapy. METHODS: We included 1,951 adult Caucasians with CHB, with or without compensated cirrhosis and without hepatocellular carcinoma (HCC) at baseline, who received entecavir/tenofovir for ≥12 months (median, six years). Kaplan-Meier estimates of cumulative survival over time were obtained. Standardized mortality ratios (SMRs) were calculated by comparing death rates with those in the Human Mortality Database. RESULTS: The one-, five-, and eight-year cumulative probabilities were 99.7, 95.9, and 94.1% for overall survival, 99.9, 98.3, and 97.4% for liver-related survival, and 99.9, 97.8, and 95.8% for transplantation-free liver-related survival, respectively. Overall mortality was independently associated with older age and HCC development, liver-related mortality was associated with HCC development only, and transplantation-free liver-related mortality was independently associated with HCC development and lower platelet levels at baseline. Baseline cirrhosis was not independently associated with any type of mortality. Compared with the general population, in all CHB patients mortality was not significantly different (SMR 0.82), whereas it was lower in patients without HCC regardless of baseline cirrhosis (SMR 0.58) and was higher in patients who developed HCC (SMR 3.09). CONCLUSION: Caucasian patients with CHB and compensated liver disease who receive long-term entecavir/tenofovir therapy have excellent overall and liver-related eight-year survival, which is similar to that of the general population. HCC is the main factor affecting their overall mortality, and is the only factor affecting their liver-related mortality. LAY SUMMARY: Caucasian patients with chronic hepatitis B with or without compensated cirrhosis who receive long-term entecavir or tenofovir therapy have excellent overall eight-year survival, which is similar to that of the general population. Hepatocellular carcinoma is the main factor affecting their overall mortality, and is the only factor affecting liver-related mortality in this setting.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Papatheodoridis GV, Sypsa V, Dalekos G, et al. Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population. J Hepatol. 2018. PMID: 29427727. doi:10.1016/j.jhep.2018.01.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。